A5069854148- Liver Disease Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Liver Disease and Transplantation
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Cancer, Lipids, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Cancer Mechanisms and Therapy
- Hepatitis Viruses Studies and Epidemiology
- Gastric Cancer Management and Outcomes
- Drug-Induced Hepatotoxicity and Protection
- Lung Cancer Treatments and Mutations
- HIV/AIDS drug development and treatment
- Liver physiology and pathology
- Gut microbiota and health
- Radiomics and Machine Learning in Medical Imaging
- Renal cell carcinoma treatment
- Gallbladder and Bile Duct Disorders
- Organ Transplantation Techniques and Outcomes
- Liver Diseases and Immunity
- Viral-associated cancers and disorders
- Systemic Lupus Erythematosus Research
National Yang Ming Chiao Tung University
2016-2025
Taipei Veterans General Hospital
2016-2025
Jiangnan University
2025
Honghu Hospital of Traditional Chinese Medicine
2025
University of Maryland, College Park
2023-2025
Physical Sciences (United States)
2023-2025
Kaohsiung Medical University
2007-2025
Kaohsiung Medical University Chung-Ho Memorial Hospital
2025
Sun Yat-sen University
2023-2024
National Clinical Research Center for Digestive Diseases
2024
Abstract Hepatocellular carcinoma (HCC) can have viral or non-viral causes 1–5 . Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stratification patients optimal response to therapy unmet need 6,7 Here we report the progressive accumulation exhausted, unconventionally activated CD8 + PD1 T cells in NASH-affected livers. In preclinical models NASH-induced therapeutic immunotherapy targeted at programmed...
Purpose The role of antiviral prophylaxis in preventing hepatitis B virus (HBV) reactivation before rituximab-based chemotherapy patients with lymphoma and resolved is unclear. Patients Methods Eighty CD20 + were randomly assigned to receive either prophylactic entecavir (ETV) 3 months after completing (ETV group, n = 41) or therapeutic ETV at the time HBV surface antigen (HBsAg) reverse seroconversion since (control 39). Results Fifty-eight (72.5%) positive for antibody, DNA was...
The Asia-Pacific Primary Liver Cancer Expert (APPLE) Consensus Statement on the treatment strategy for patients with intermediate-stage hepatocellular carcinoma (HCC) was established August 31, 2019, in Sapporo, Hokkaido during 10th Annual APPLE Meeting. This manuscript summarizes international consensus statements developed at 2019. Transarterial chemoembolization (TACE) is only guideline-recommended global standard of care HCC. However, not all benefit from TACE because HCC a heterogeneous...
Abstract Background & Aims Oral antiviral therapy may reduce the disease progression of chronic hepatitis B ( CHB ) patients. We aimed to further investigate efficacy long‐term entecavir in reduction risk hepatocellular carcinoma HCC ), cirrhotic events and mortality a large group ‐related cirrhosis Methods The C‐ TEAM (Cirrhosis‐Taiwanese EntecAvir Multicenter) study was nationwide, multicenter, retrospective–prospective cohort Taiwan. enrolled treatment‐naïve patients with baseline HBV...
Atezolizumab plus bevacizumab (AtezoBev) is the standard of care for first-line treatment unresectable HCC. No evidence exists as to its use in routine clinical practice patients with impaired liver function.
Background Immune checkpoint inhibitors (ICIs) are promising agents for unresectable hepatocellular carcinoma (uHCC), but lack effective biomarker to predict outcomes. The gut microbiome can modulate tumor response immunotherapy, its effect on HCC remains unclear. Methods From May 2018 February 2020, patients receiving ICI treatment uHCC were prospectively enrolled; their fecal samples collected before treatment. microbiota and metabolites analyzed from 20 with radiology-proven objective...
Background and Aims: A single-nation study reported that pretreatment HBV viral load is associated with on-treatment risk of HCC in patients who are HBeAg-positive without cirrhosis chronic hepatitis B initiating antiviral treatment. We aimed to validate the association between baseline a larger, multinational cohort. Approach Results: Using cohort from Korea, Hong Kong, Taiwan involving 7545 adult HBeAg-positive, started entecavir or tenofovir treatment ≥5.00 log 10 IU/mL, was estimated by...
Performance status is included in the Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma (HCC). Few studies specifically evaluated role of performance patients with HCC. This study investigated its distribution, determinants, and prognostic impact, aiming to improve BCLC system. A total 2,381 HCC were enrolled. was determined according Eastern Cooperative Oncology Group scale. The ability original three modified systems compared by Akaike information criterion (AIC)....
To evaluate the efficacy of surgical resection (SR) and radiofrequency ablation (RFA) for single hepatocellular carcinoma (HCC) 2 cm or less.The optimal management Barcelona Clínic Liver Cancer (BCLC) very early-stage HCC is undetermined.Between 2002 2013, a total 237 (SR, 109; RFA, 128) patients with BCLC were enrolled. Their overall survival (OS) recurrence-free (RFS) compared. Propensity score matching analysis identified 79 matched pairs to compare outcomes.At baseline, SR younger had...
The severity of liver dysfunction in hepatocellular carcinoma (HCC) is often estimated with Child-Turcotte-Pugh (CTP) classification or model for end-stage disease (MELD) score. We aim to investigate the performance albumin-bilirubin (ALBI) and platelet-albumin-bilirubin (PALBI) grade, which are recently reported be simple objective measurements reserve HCC.Between 2002 2014, consecutive 3182 HCC patients were enrolled follow up their survival. area under receiver-operator-characteristic...
Background and Aims The fatty liver index (FLI) is an algorithm involving the waist circumference, body mass index, serum levels of triglyceride gamma-glutamyl transferase to identify liver. Although some studies have attempted validate FLI, few been conducted for external validation among Asians. We FLI predict ultrasonographic in Taiwanese subjects. Methods enrolled consecutive subjects who received health check-up services at Taipei Veterans General Hospital from 2002 2009....